Apollomics, Inc. (NASDAQ:APLM) Short Interest Update

Apollomics, Inc. (NASDAQ:APLM) saw a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 10,800 shares, a decrease of 50.5% from the December 31st total of 21,800 shares. Currently, 1.6% of the company’s shares are short sold. Based on an average trading volume of 309,200 shares, the days-to-cover ratio is currently 0.0 days.

Apollomics Stock Down 4.5 %

NASDAQ APLM traded down $0.41 during trading on Thursday, reaching $8.70. 18,706 shares of the stock traded hands, compared to its average volume of 19,862. Apollomics has a fifty-two week low of $6.50 and a fifty-two week high of $85.00. The stock’s 50-day moving average price is $9.51 and its 200 day moving average price is $12.82.

Institutional Trading of Apollomics

A hedge fund recently raised its stake in Apollomics stock. Exchange Traded Concepts LLC raised its position in Apollomics, Inc. (NASDAQ:APLM) by 247.1% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 1,259,117 shares of the company’s stock after acquiring an additional 896,316 shares during the period. Exchange Traded Concepts LLC owned about 1.41% of Apollomics worth $179,000 as of its most recent filing with the SEC. Institutional investors own 19.13% of the company’s stock.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.